Economic burden of Huntington disease in Europe and the USA: Results from the Huntington's Disease Burden of Illness study
Open Access
- 8 December 2022
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 30 (4) , 1109-1117
Abstract
Background and purpose: The prevalence of Huntington disease (HD) has increased over time; however, there is a lack of up‐to‐date evidence documenting the economic burden of HD by disease stage. This study provides an estimate of the annual direct medical, nonmedical, and indirect costs associated with HD from participants in the Huntington's Disease Burden of Illness (HDBOI) study in five European countries and the USA.Methods: The HDBOI is a retrospective, cross‐sectional study. Data collection was conducted between September 2020 and May 2021. Participants were recruited by their HD‐treating physicians and categorized as early stage (ES), mid stage (MS), or advanced stage (AS) HD. Data were collected via three questionnaires: a case report form, completed by physicians who collected health care resource use associated with HD to compute direct medical cost, and optional patient and caregiver questionnaires, which included information used to compute nondirect medical and indirect costs. Country‐specific unit cost sources were used.Results: HDBOI cost estimates were €12,663 (n = 2094) for direct medical costs, €2984 (n = 359) for nondirect medical costs, and €47,576 (n = 436) for indirect costs. Costs are higher in patients who are at later stages of disease; for example, direct medical costs estimates were €9220 (n = 846), €11,885 (n = 701), and €18,985 (n = 547) for ES, MS, and AS, respectively. Similar trends were observed for nondirect and indirect costs. Costs show large variations between patients and countries.Conclusions: Cost estimates from the HDBOI study show that people with HD and their caregivers bear a large economic burden that increases as disease progresses.Keywords
Funding Information
- Roche
This publication has 14 references indexed in Scilit:
- The societal cost of Huntington's disease: are we underestimating the burden?European Journal of Neurology, 2016
- The Prevalence of Huntington's DiseaseNeuroepidemiology, 2016
- Premanifest and Early Huntington’s Disease2014
- The direct medical costs of Huntington’s disease by stage. A retrospective commercial and Medicaid claims data analysisJournal of Medical Economics, 2013
- Monetary Costs of Dementia in the United StatesNew England Journal of Medicine, 2013
- The current and projected economic burden of Parkinson's disease in the United StatesMovement Disorders, 2013
- Age, CAG repeat length, and clinical progression in Huntington's diseaseMovement Disorders, 2011
- The economic burden of advanced Parkinson’s disease: an analysis of a UK patient datasetJournal of Medical Economics, 2010
- Huntington's diseaseBMJ, 2010
- Predictors of nursing home placement in Huntington diseaseNeurology, 2003